**Name of Journal: *World Journal of Gastrointestinal Endoscopy***

**Manuscript NO: 37119**

**Manuscript Type: Minireviews**

**Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts**

Li F *et al*. Confocal endomicroscopy and cyst fluid molecular analysis

**Feng Li, Ahmad Malli, Zobeida Cruz-Monserrate, Darwin Conwell, Somashekar G Krishna**

**Feng Li, Ahmad Malli, Zobeida Cruz-Monserrate, Darwin Conwell, Somashekar G Krishna,** Division of Gastroenterology, Hepatology, and Nutrition, Ohio State University Wexner Medical Center, Columbus, OH 43210, United States

**ORCID number:** Feng Li (0000-0003-2006-678X); Ahmad Malli (0000-0001-8130-138X); Darwin Conwell (0000-0003-0449-3730); Zobeida Cruz-Monserrate (0000-0003-0849-655X); Somashekar G Krishna (0000-0001-5748-7890).

**Author contributions:** Li F contributed to conception, design, drafting of the article and critical revision of the article for important intellectual content; Malli A contributed to critical revision of the article for important intellectual content; Cruz-Monserrate Z contributed to critical revision of the article for important intellectual content; Conwell D contributed to critical revision of the article for important intellectual content; Krishna S contributed to conception, design, drafting of the article, critical revision of the article for important intellectual content and final approval of the article.

**Conflict-of-interest** **statement:** There are no relevant conflicts of interest to report for any author.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Dr. Somashekar G Krishna, MD, Assistant Professor, Doctor,** Division of Gastroenterology, Hepatology and Nutrition, Ohio State University Wexner Medical Center, 395 W. 12th Avenue, 2nd floor Office Tower,Columbus, OH 43210, United States.somashekar.krishna@osumc.edu

**Telephone:** +1-614-2936255

**Fax:** +1-614-2930861

**Received:** November 14, 2017

**Peer-review started:** November 17, 2017

**First decision:** December 6, 2017

**Revised:** December 11, 2017

**Accepted:** December 29, 2017

**Article in press:**

**Published online:**

**Abstract**

Increases in the quality as well as utilization of cross-sectional imaging have led to rising diagnoses of pancreatic cystic lesions (PCL). Accurate pre-surgical diagnosis enables appropriate triage of PCLs. Unfortunately, current diagnostic approaches have suboptimal accuracy and may lead to unnecessary surgical resections or missed diagnoses of advanced neoplasia. Additionally, early detection represents an opportunity for intervention to prevent the progression to pancreatic adenocarcinoma. Our aim for this review is to systematically review the current literature on confocal endomicroscopy and molecular biomarkers in the evaluation of PCLs. Confocal laser endomicroscopy is a novel technology that allows for real-time *in vivo* microscopic imaging with multiple clinical trials identifying characteristic endomicroscopy findings of various pancreatic cystic lesions. DNA-based molecular markers have also emerged as another diagnostic modality as the pattern of genetic alternations present in cyst fluid can provide both diagnostic and prognostic data. We propose that both techniques can be utilized to improve patient outcomes.

**Key words:** Pancreas; Pancreatic cyst; Pancreatic adenocarcinoma; Confocal endomicroscopy; Next generation sequencing; Molecular marker

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Current diagnostic guidelines for the evaluation of pancreatic cystic lesions have suboptimal accuracy and may lead to unnecessary surgical resections or missed diagnoses of advanced neoplasia. We propose that two new diagnostic technologies, confocal laser endomicroscopy and DNA-based molecular markers, may be used synergistically to improve diagnostic accuracy. In this review, we summarize the current literature regarding these two techniques.

Li F, Malli A, Cruz-Monserrate Z, Conwell D, Krishna SG. Confocal endomicroscopy and cyst fluid molecular analysis: Comprehensive evaluation of pancreatic cysts. *World J Gastrointest Endosc* 2017; In press

**INTRODUCTION**

Increases in the quality as well as utilization of cross-sectional imaging have led to rising diagnoses of pancreatic cystic lesions (PCL) with a reported incidence ranging from 2.4%-19.6%[1-3]. Unfortunately, current diagnostic approaches have suboptimal accuracy and may lead to unnecessary surgical resections or missed diagnoses of advanced neoplasia[4]. Accurate pre-surgical diagnosis enables appropriate triage of PCLs, allowing for surveillance of lower-risk lesions and surgical resection of high-risk lesions. Additionally, early detection represents an opportunity for intervention to prevent the progression to pancreatic adenocarcinoma.

Our aim for this review is to summarize the current literature on confocal endomicroscopy and molecular biomarkers in the evaluation of PCLs. We propose that both techniques can be complementary to improve patient outcomes.

**CURRENT KNOWLEDGE**

Pancreatic cysts can be divided into mucinous cysts [intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN)], non-mucinous cystic neoplasms [serous cystadenoma (SCA), pseudocysts], cystic neuroendocrine tumors (cystic-NETs), and solid pseudopapillary neoplasm (SPN)[5]. Each of these lesions have unique characteristics and malignancy potential requiring different management strategies.

The current standard of care in the evaluation of PCLs utilizes a multimodality approach, including clinical and radiographic assessment, Endoscopic ultrasound (EUS)-guided fine needle aspiration (EUS-FNA), cyst fluid analysis (*i.e.* tumor markers such as CEA), and cytology. Despite these techniques, the pre-surgical differentiation of PCLs remains challenging with continued need for improved diagnostic accuracy. A landmark prospective study comparing cyst fluid CEA, cytology, and EUS showed that that cyst fluid CEA > 192 ng/mL had a diagnostic accuracy of 79.2%, cytology had a diagnostic accuracy of 58.7%, and EUS morphology had a diagnostic accuracy of 50.9%[6]. However, a more recent, larger multicenter retrospective study showed that a CEA cutoff of 192 ng/mL for diagnosis of mucinous cysts resulted in a sensitivity of only 61%[7].

In an effort to improve diagnostic accuracy, multiple guidelines have been developed over the past decade to assist in the management of PCLs, including the International Consensus Guidelines (Sendai 2006, Fukuoka 2012, and 2017 revision of the Fukuoka guidelines) and the American Gastroenterological Association (AGA) 2015 guidelines[8-10]. The 2006 Sendai guidelines recommended surgical resection of any suspected MCN, main duct IPMN, or mixed duct IPMN. Additional criteria for surgical resection included: clinical symptoms, dilated pancreatic duct (≥ 6 mm), intracystic mural nodules, or positive cytology[8]. While the Sendai guidelines have a sensitivity approaching 100%, specificity is limited, ranging from 23%-31%[11,12]. In 2012, stricter surgical criteria were developed for the revised Fukuoka guidelines for IPMN and MCN including: pancreatic duct ≥ 10 mm, presence of an enhancing solid component, obstructive jaundice with a pancreatic cyst[9]. Although the Fukuoka guidelines were more specific compared to the Sendai guidelines, sensitivity was decreased. In a retrospective analysis, the updated Fukuoka (2012) guidelines were not superior to the Sendai guidelines for detection of invasive carcinoma or high-grade dysplasia[13].

Given these limitations, the AGA introduced guidelines in 2015 for the management of all asymptomatic neoplastic pancreatic cysts, whereas neither the Sendai nor the Fukuoka guidelines address the management of non-mucinous cysts. Compared to the Fukuoka guidelines, the AGA guidelines have a higher threshold for both endoscopic evaluation and surgical resection. EUS-FNA was recommended if 2 high-risk features were present, including size ≥ 3 cm, a dilated main pancreatic duct, or associated solid component. Surgical resection was recommended if a cyst had both a solid component and a dilated pancreatic duct and/or concerning features on EUS-FNA[10]. In a retrospective study of 225 patients who underwent EUS-FNA for pancreatic cysts, applying the AGA criteria detected advanced neoplasia with 62% sensitivity, 79% specificity, 57% positive predictive value, and 82% negative predictive value. Unfortunately, 45% of IPMNs with adenocarcinoma or high-grade dysplasia were missed[14].

In 2017, the International Consensus Group released updated guidelines regarding the prediction of invasive carcinoma and high-grade dysplasia, as well as the surveillance and post-operative follow-up of IPMNs. In the revised guidelines, increased serum CA19-9 and cyst growth rate greater than 5 mm in diameter over 2 years were added as “worrisome features” for BD-IPMN. These limitations show that current guidelines are suboptimal to accurately diagnose PCLs and additional imaging and molecular biomarkers are necessary to improve diagnostic accuracy of these increasingly prevalent lesions. EUS-guided needle-based confocal laser endomicroscopy (nCLE) and pancreatic cyst fluid molecular markers are promising new diagnostic modalities to aid in diagnosis and management of PCLs.

***Imaging biomarkers for the evaluation of pancreatic cystic lesions***

CLE) is a novel technology that allows for real-time *in vivo* microscopic imaging. The CLE probe can be inserted through a 19-gauge FNA needle for real-time microscopic examination of the pancreatic cyst epithelium during EUS.

Multiple clinical trials have identified characteristic nCLE findings of various pancreatic cystic lesions (Table 1). For IPMN and MCN, characteristic findings include finger-like papillae and a single or layers of band-like epithelium, respectively[15-17]. *In vivo* and *ex vivo* nCLE findings for IPMN have been validated compared to surgical pathology as gold standard[18]. The finding of a “superficial vascular network” or “fern pattern” is highly specific for SCA[19,20]. Pseudocysts contain bright particles, corresponding to inflammatory cells, against a dark background due to the lack of a true cyst wall[17]. Cystic neuroendocrine tumors demonstrate high cellularity demonstrating trabeculae or cords of cells separated by fibrous bands[18]. More rare cystic lesions, such as those lined by squamous epithelium (lymphoepithelial cysts) have been characterized in case reports[21, 22].

The INSPECT study was a pilot to assess the feasibility of nCLE in differentiating mucinous PCLs and establish safety[15]. The DETECT study’s aim was to identify the feasibility, safety, diagnostic yield of cystoscopy and nCLE to diagnose PCLs using the consensus criteria developed for the INSPECT trial. The patients included in the study had clinical diagnoses of IPMN, MCN, pseudocyst, lymphoepithelial cyst, and retention cyst. The diagnosis of IPMN was supported by the identification of finger-like papillae[23]. The CONTACT-1 trial enrolled 31 patients with solitary pancreatic cystic lesions who underwent EUS-nCLE. The nCLE finding of a superficial vascular network, which correlated microscopically to a dense and subepithelial capillary vascularization, was only seen in SCA[19]. The CONTACT-2 study identified new nCLE criteria for MCN (epithelial bands), pancreatic pseudocysts (field of bright particles), and cystic neuroendocrine neoplasm (black cell clusters with white fibrous areas), which correlated with histologic features[17]. The INDEX trial validated the previously described nCLE findings in *ex vivo* CLE of resected PCLs; demonstrated substantial interobserver agreement for mucinous PCLs among nCLE-naïve observers; and established an ”almost perfect“ interobserver agreement and intraobserver reliability among external blinded observers for the detection of mucinous PCLs[24]. Based on the above studies and our experience, we have suggested an algorithm for evaluation of a PCL utilizing EUS-nCLE (Figure 1).

***Pancreatic cyst fluid molecular biomarkers***

Over the last decade, DNA-based molecular testing has emerged as a potent diagnostic modality for the assessment of PCLs. Analyzing the DNA present in the cyst fluid for the pattern of genetic alterations can provide both diagnostic and prognostic data regarding likelihood of progression to pancreatic adenocarcinoma[25,26].

There are three main components of molecular analysis: DNA quantity and quality, oncogenic mutations, loss of heterozygosity (LOH) of tumor suppressor genes. DNA quantity is determined by spectrophotometric analysis. By exposing the DNA sample to ultraviolet light, a photo-detector can be used to determine the quantity of nucleic acid in the sample. The concentration of DNA can be determined using the optical density ratio at a certain wavelength (260 of 280) light after extracting DNA from fluid. In a study of 113 patients with pancreatic cysts, elevated amounts of cyst fluid DNA were associated with malignancy[27]. Loss of heterozygosity results in loss of the entire gene and the surrounding chromosomal region. The detection of LOH by using microsatellite markers closely linked to key tumor suppressor genes correlates with gene inactivation and mutation, resulting in loss of tumor suppressor activity and development of malignancy[28].

Prior studies evaluating DNA testing of PCL fluid were limited by insensitive detection strategies (conventional Sanger sequencing). The use of next-generation sequencing (NGS) has revealed specific molecular markers that aid in the diagnosis of mucinous cysts as well as detection of advanced neoplasia. NGS refers to DNA sequencing technologies that allow sequencing of numerous small fragments of DNA in parallel, which are then pieced together by mapping individual reads to the reference genome. This allows rapid sequencing of entire genomes compared to conventional Sanger sequencing. Whole exome and targeted sequencing studies of PCL fluid have revealed certain mutational profiles of major cyst subtypes as well as markers of advanced neoplasia (high-grade dysplasia/pancreatic adenocarcinoma).

More widespread utilization of NGS is limited by suboptimal identification of specific PCL types, including MCN (low sensitivity) and cystic neuroendocrine tumor (lack of DNA) as well as poor sensitivity for detection of the *VHL* gene (as seen in SCAs) requiring Sanger sequencing[8,29]. A proposed algorithm for evaluation of PCLs based on cyst fluid molecular markers is shown in Figure 2.

KRAS mutations are seen in both IPMN and MCN, although less sensitive for detection of MCN[30]. GNAS mutations are found in IPMN but not MCN[25,31]. RNF43 mutations occur in 14%-38% of IPMNs[25,31]. VHL gene mutations have been identified in SCA but not in other pancreatic cystic lesions[25,29]. CTNNB1 gene mutations are the most commonly seen alteration in SPN[25].

***Integration of imaging and molecular biomarkers for the evaluation of PCLs***

EUS guided evaluation of PCLs permits integrated evaluation with imaging (nCLE) and molecular (cyst fluid) biomarkers. Table 2 and Figure 3 summarize the key imaging and molecular biomarkers for different types of PCLs.

***Types of pancreatic cystic lesions***

**Intra-ductal papillary mucinous neoplasm:** IPMNs are epithelial neoplasms that produce mucin. They are classified based on involvement of the main pancreatic duct: main duct IPMN (MD-IPMN), branch duct IPMN (BD-IPMN), mixed (both main and branch duct) IPMN. MD-IPMN is characterized by either segmental or diffuse dilation of the main pancreatic duct greater than 5 mm without other causes of obstruction. BD-IPMN is characterized by cyst diameter greater than 5 mm that communicates with the main pancreatic duct. Mixed-IPMN meets criteria for both MD-IPMN and BD-IPMN. MD-IPMN and mixed IPMN are associated with significantly higher incidence of malignancy compared to BD-IPMN (60% *vs* 25%)[9,32].They are also classified into gastric, intestinal, pancreaticobiliary, oncocytic subtypes[33].

Patterns of papillae or epithelial bands on nCLE have high correlation with mucinous cysts[15,17]. The epithelial bands typically seen in MCNs do not have papillary morphology. On the other hand, IPMNs have complete papillae[24]. Analysis of performance of nCLE criteria for IPMN showed an accuracy 90%, sensitivity 80%, specificity 92%, positive predictive value 67%, and 96% negative predictive value[17].

The oncogenic KRAS and GNAS mutations have been extensively studied in IPMNs. The KRAS mutation is seen in 80% of IPMNs while 65% of IPMNs have mutations in the GNAS oncogene[34]. KRAS mutations are associated with branch duct location[30], while GNAS mutations are associated with main duct location[29]. KRAS and GNAS are considered early events in the progression to PDAC and mutations in either KRAS or GNAS are seen in over 96% of IPMNs[29].

In addition, inactivating mutations of the tumor suppressor gene RNF43 occur in 14%-38% of IPMNs[25,31]. Additional molecular markers present in IPMNs include p16 (lost earlier compared to p53), SMAD4, p53, and TP53[35-38].

IPMNs with advanced neoplasia may have TP53, PIK3CA, PTEN, and/or AKT1 mutations[36,39-43]. A prospective single center study showed that a combination of KRAS/GNAS mutations and changes in TP53/PIK3CA/PTEN had 78% sensitivity and 97% specificity for advanced neoplasia[44]. Studies combining DNA quantity, KRAS mutations, and LOH mutations have shown variable sensitivities: 50%[45] *vs* 83%[46]. An additional study found that both KRAS and LOH was present in 50% of carcinoma or high grade dysplasia compared to 8% of premalignant IPMNs, indicating the progression of neoplasia may correlate with accumulation of genetic disturbances[38].

**Mucinous cystic neoplasm**: Like IPMNs, MCNs are also mucin-producing epithelial neoplasms. Typically they are located in the body or tail of the pancreas and are not associated with the main pancreatic duct[47]. They are more commonly seen in women and typically occur between the ages of 30 to 50 years of age[34]. Microscopically, MCNs are composed of columnar mucinous epithelium and characteristic dense ovarian-type stroma, which express hormone receptors.

During EUS-nCLE, MCNs typically demonstrate single or layers of epithelial bands rather than papillae[17]. In a minority of patients, some MCN show evidence of chronic inflammation with bright fluorescent inflammatory cells[24].

Similar to IPMNs, the most common mutation in MCNs is the *KRAS* gene. The prevalence of KRAS mutations increases with the degree of dysplasia: 26% in low-grade MCNs but 89% in advanced neoplasia[25]. Mutations or deletions in TP53, PIK3CA, PTE, CDKN2A, SMAD4 are associated with advanced neoplasia in MCN[31]. Unlike IPMNs, the GNAS mutation is not seen in MCNs[25,31].

Although the KRAS mutation is seen in both IPMN and MCN, it is much less sensitive for detection of MCN (sensitivity of 14%) than IPMN[30]. Other genetic alterations in MCNs include *KRAS*, *TP53*, and *SMAD4*. Additional associations with *PIK3CA*, *PTEN*, and *CKDN2A* have also been published [25,31,40].

***Serous cystadenoma***

Serous cystadenomas are benign cystic neoplasms that are more common in women[48]. A large retrospective, multinational study of over 2600 patients diagnosed with serous cystic neoplasms showed minimal risk of clinically relevant symptoms over a three-year follow up period. Given their lack of malignant potential, surgical management is only needed if they are symptomatic (causing pancreatitis or jaundice)[48].

A report from the CONTACT study identified a superficial vascular network (subepithelial vessels uniformly distributed in the cyst wall) or fern pattern as a characteristic of SCA[19,49]. The presence of this pattern is highly specific for SCA. On the other hand, sensitivity for diagnosis of SCA is low in the absence of this pattern (69% to 75%)[17,19].

VHL gene mutations have been identified in SCA cyst fluid[29] but not in IPMN, MCN, or SPN[25]. However, VHL mutations are also seen in pancreatic neuroendocrine tumors and are not specific to SCAs. TP53 and PIK3CA have been rarely described. KRAS, GNAS, and RNF43 mutations, which can be seen in mucinous cysts, have not been identified[25,29].

***Solid pseudopapillary neoplasm***

Solid pseudopapillary neoplasmsare typically well-defined solitary lesions often found in younger women[50]. Microscopically, they are composed of poorly cohesive cells forming a mixed pattern of solid, pseudopapillary, and hemorrhagic cystic structures[34]. They do not communicate with the main pancreatic duct and contain myxoid stroma on cytology[47].

The nCLE findings of solid pseudopapillary neoplasms are not well defined due to their rarity.

Mutations of the B-catenin gene (CTNNB1) are the most commonly seen alteration in SPN[25]. This results in cytoplasmic and nuclear accumulation of B-catenin. VHL, GNAS, RNF43 mutations have not been identified in these cysts[25,29]. Therefore, the presence of CTNNB1 in the absence of KRAS, GNAS, and RNF43 mutations is confirmatory for diagnosing SPNs[25].

***Pancreatic pseudocyst***

Pancreatic pseudocysts are an encapsulated collections of fluid with a well-defined inflammatory wall with minimal or no necrosis[51]. They are histologically composed of fibro-inflammatory tissue surrounding necrotic adipocytes without epithelial lining. No vasculature is seen because pseudocysts do not have an epithelium. On nCLE, this is characterized by bright inflammatory cells against a dark background[17]. As pseudocysts are not neoplastic, molecular markers related to malignancy are not found.

***Cystic neuroendocrine neoplasms***

Microscopically, cystic neuroendocrine neoplasms are characterized by a neoplastic monomorphic cell proliferation with variations in cellular architecture. Characteristic nCLE appearance of pancreatic neuroendocrine tumors have been described[21]. Endomicroscopy demonstrates dark, irregular clusters or trabeculae of compact cells (neoplastic cells) surrounded by gray tissue (fibrovascular stroma)[17]. Neuroendocrine neoplasms have not been well characterized on molecular studies and further research is needed.

**CONCLUSION**

This review summarizes the current status of new technologies for the evaluation of PCLs including confocal endomicroscopy and molecular markers. Both EUS-nCLE and cyst fluid molecular analysis of PCLs represent promising new modalities to improve the diagnostic evaluation of PCLs by supplement the standard evaluation of pancreatic cysts which includes imaging (MRI, CT) and endoscopy (EUS). Given the limitations of current diagnostic algorithms, these imaging and molecular biomarkers can increase diagnostic accuracy and improve management of PCLs. Prospective multicenter studies are needed to determine how to integrate nCLE and molecular analysis into existing management protocols and clinical practice. In clinical practice, these technologies may especially be applied in the setting of cases with diagnostic uncertainty in order to improve accuracy and allow for appropriate risk stratification. Expertise in these technologies may not be widespread and referral to centers with experience may be necessary.

**REFERENCES**

1 **de Jong K**, Nio CY, Hermans JJ, Dijkgraaf MG, Gouma DJ, van Eijck CH, van Heel E, Klass G, Fockens P, Bruno MJ. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. *Clin Gastroenterol Hepatol* 2010; **8**: 806-811 [PMID: 20621679 DOI: 10.1016/j.cgh.2010.05.017]

2 **Laffan TA**, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK, Hruban RH. Prevalence of unsuspected pancreatic cysts on MDCT. *AJR Am J Roentgenol* 2008; **191**: 802-807 [PMID: 18716113 DOI: 10.2214/AJR.07.3340]

3 **Zhang XM**, Mitchell DG, Dohke M, Holland GA, Parker L. Pancreatic cysts: depiction on single-shot fast spin-echo MR images. *Radiology* 2002; **223**: 547-553 [PMID: 11997566 DOI: 10.1148/radiol.2232010815]

4 **Matthaei H**, Schulick RD, Hruban RH, Maitra A. Cystic precursors to invasive pancreatic cancer. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 141-150 [PMID: 21383670 DOI: 10.1038/nrgastro.2011.2]

5 **Zamboni G,** Klöppel G, Hruban R, Longnecker D, Adler G. Mucinous cystic neoplasms of the pancreas: IARC Press, 2000

6 **Brugge WR**, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. *Gastroenterology* 2004; **126**: 1330-1336 [PMID: 15131794 DOI: 10.1053/j.gastro.2004.02.013]

7 **Gaddam S**, Ge PS, Keach JW, Mullady D, Fukami N, Edmundowicz SA, Azar RR, Shah RJ, Murad FM, Kushnir VM, Watson RR, Ghassemi KF, Sedarat A, Komanduri S, Jaiyeola DM, Brauer BC, Yen RD, Amateau SK, Hosford L, Hollander T, Donahue TR, Schulick RD, Edil BH, McCarter M, Gajdos C, Attwell A, Muthusamy VR, Early DS, Wani S. Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter study. *Gastrointest Endosc* 2015; **82**: 1060-1069 [PMID: 26077458 DOI: 10.1016/j.gie.2015.04.040]

8 **Tanaka M**, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S; International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatology* 2006; **6**: 17-32 [PMID: 16327281 DOI: 10.1159/000090023]

9 **Tanaka M**, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology* 2012; **12**: 183-197 [PMID: 22687371 DOI: 10.1016/j.pan.2012.04.004]

10 **Vege SS**, Ziring B, Jain R, Moayyedi P; Clinical Guidelines Committee; American Gastroenterology Association. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology* 2015; **148**: 819-22; quize12-3 [PMID: 25805375 DOI: 10.1053/j.gastro.2015.01.015]

11 **Pelaez-Luna M**, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, Pearson RK, Petersen BT, Topazian MD, Vege SS, Kendrick M, Farnell MB. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. *Am J Gastroenterol* 2007; **102**: 1759-1764 [PMID: 17686073 DOI: 10.1111/j.1572-0241.2007.01224.x]

12 **Tang RS**, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, Chaudhari V, Raman S, Farrell JJ. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. *Clin Gastroenterol Hepatol* 2008; **6**: 815-819; quiz 719 [PMID: 18602036 DOI: 10.1016/j.cgh.2008.04.005]

13 **Kaimakliotis P**, Riff B, Pourmand K, Chandrasekhara V, Furth EE, Siegelman ES, Drebin J, Vollmer CM, Kochman ML, Ginsberg GG, Ahmad NA. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. *Clin Gastroenterol Hepatol* 2015; **13**: 1808-1815 [PMID: 25818077 DOI: 10.1016/j.cgh.2015.03.017]

14 **Singhi AD**, Zeh HJ, Brand RE, Nikiforova MN, Chennat JS, Fasanella KE, Khalid A, Papachristou GI, Slivka A, Hogg M, Lee KK, Tsung A, Zureikat AH, McGrath K. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. *Gastrointest Endosc* 2016; **83**: 1107-1117.e2 [PMID: 26709110 DOI: 10.1016/j.gie.2015.12.009]

15 **Konda VJ**, Meining A, Jamil LH, Giovannini M, Hwang JH, Wallace MB, Chang KJ, Siddiqui UD, Hart J, Lo SK, Saunders MD, Aslanian HR, Wroblewski K, Waxman I. A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. *Endoscopy* 2013; **45**: 1006-1013 [PMID: 24163192 DOI: 10.1055/s-0033-1344714]

16 **Modi RM,** Kamboj AK, Swanson B, Conwell DL, Krishna SG. Novel technique for diagnosis of mucinous cystic neoplasms: in vivo and ex vivo confocal laser endomicroscopy. *VideoGIE* **2**: 55-56 [DOI: 10.1016/j.vgie.2016.12.003]

17 **Napoleon B**, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Poizat F, Giovannini M. In vivo characterization of pancreatic cystic lesions by needle-based confocal laser endomicroscopy (nCLE): proposition of a comprehensive nCLE classification confirmed by an external retrospective evaluation. *Surg Endosc* 2016; **30**: 2603-2612 [PMID: 26428198 DOI: 10.1007/s00464-015-4510-5]

18 **Krishna SG**, Swanson B, Conwell DL, Muscarella P 2nd. In vivo and ex vivo needle-based confocal endomicroscopy of intraductal papillary mucinous neoplasm of the pancreas. *Gastrointest Endosc* 2015; **82**: 571-572 [PMID: 26005013 DOI: 10.1016/j.gie.2015.04.021]

19 **Napoléon B**, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Filoche B, Giovannini M. A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. *Endoscopy* 2015; **47**: 26-32 [PMID: 25325684 DOI: 10.1055/s-0034-1390693]

20 **Modi RM**, Swanson B, Muscarella P 2nd, Conwell DL, Krishna SG. Novel techniques for diagnosis of serous cystadenoma: fern pattern of vascularity confirmed by in vivo and ex vivo confocal laser endomicroscopy. *Gastrointest Endosc* 2017; **85**: 258-259 [PMID: 27449195 DOI: 10.1016/j.gie.2016.07.015]

21 **Kamboj AK**, Swanson B, Dillhoff ME, Conwell DL, Krishna SG. Cystic pancreatic neuroendocrine tumors: correlation of in vivo needle-based confocal endomicroscopic findings by ex vivo analysis. *Gastrointest Endosc* 2017; **85**: 259-260 [PMID: 27492715 DOI: 10.1016/j.gie.2016.07.055]

22 **Modi RM**, Kamboj AK, Swanson B, Conwell DL, Krishna SG. Epidermoid cyst within an intrapancreatic accessory spleen: endosonography and confocal endomicroscopy of an unusual pancreatic cystic lesion. *Endoscopy* 2016; **48**: E332-E333 [PMID: 27741530 DOI: 10.1055/s-0042-117506]

23 **Nakai Y**, Iwashita T, Park DH, Samarasena JB, Lee JG, Chang KJ. Diagnosis of pancreatic cysts: EUS-guided, through-the-needle confocal laser-induced endomicroscopy and cystoscopy trial: DETECT study. *Gastrointest Endosc* 2015; **81**: 1204-1214 [PMID: 25634486 DOI: 10.1016/j.gie.2014.10.025]

24 **Krishna SG**, Swanson B, Hart PA, El-Dika S, Walker JP, McCarthy ST, Malli A, Shah ZK, Conwell DL. Validation of diagnostic characteristics of needle based confocal laser endomicroscopy in differentiation of pancreatic cystic lesions. *Endosc Int Open* 2016; **4**: E1124-E1135 [PMID: 27853737 DOI: 10.1055/s-0042-116491]

25 **Springer S**, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology* 2015; **149**: 1501-1510 [PMID: 26253305 DOI: 10.1053/j.gastro.2015.07.041]

26 **Khalid A**, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. *Am J Gastroenterol* 2007; **102**: 2339-2349 [PMID: 17764489 DOI: 10.1111/j.1572-0241.2007.01516.x]

27 **Khalid A**, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, Brugge WR, Edmundowicz SA, Hawes RH, McGrath KM. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. *Gastrointest Endosc* 2009; **69**: 1095-1102 [PMID: 19152896 DOI: 10.1016/j.gie.2008.07.033]

28 **Khalid A**, Pal R, Sasatomi E, Swalsky P, Slivka A, Whitcomb D, Finkelstein S. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. *Gut* 2004; **53**: 1860-1865 [PMID: 15542529 DOI: 10.1136/gut.2004.039784]

29 **Wu J**, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011; **3**: 92ra66 [PMID: 21775669 DOI: 10.1126/scitranslmed.3002543]

30 **Nikiforova MN**, Khalid A, Fasanella KE, McGrath KM, Brand RE, Chennat JS, Slivka A, Zeh HJ, Zureikat AH, Krasinskas AM, Ohori NP, Schoedel KE, Navina S, Mantha GS, Pai RK, Singhi AD. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. *Mod Pathol* 2013; **26**: 1478-1487 [PMID: 23743931 DOI: 10.1038/modpathol.2013.91]

31 **Wu J**, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci USA* 2011; **108**: 21188-21193 [PMID: 22158988 DOI: 10.1073/pnas.1118046108]

32 **Crippa S**, Fernández-Del Castillo C, Salvia R, Finkelstein D, Bassi C, Domínguez I, Muzikansky A, Thayer SP, Falconi M, Mino-Kenudson M, Capelli P, Lauwers GY, Partelli S, Pederzoli P, Warshaw AL. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. *Clin Gastroenterol Hepatol* 2010; **8**: 213-219 [PMID: 19835989 DOI: 10.1016/j.cgh.2009.10.001]

33 **Machado NO**, Al Qadhi H, Al Wahibi K. Intraductal Papillary Mucinous Neoplasm of Pancreas. *N Am J Med Sci* 2015; **7**: 160-175 [PMID: 26110127 DOI: 10.4103/1947-2714.157477]

34 **Singhi AD**, Nikiforova MN, McGrath K. DNA testing of pancreatic cyst fluid: is it ready for prime time? *Lancet Gastroenterol Hepatol* 2017; **2**: 63-72 [PMID: 28404017 DOI: 10.1016/S2468-1253(16)30084-X]

35 **Biankin AV**, Biankin SA, Kench JG, Morey AL, Lee CS, Head DR, Eckstein RP, Hugh TB, Henshall SM, Sutherland RL. Aberrant p16 (INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. *Gut* 2002; **50**: 861-868 [PMID: 12010891 DOI: 10.1136/gut.50.6.861]

36 **Kanda M**, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, Lee J, Kamel I, Lennon AM, Knight S, Fujiwara S, Hruban RH, Canto MI, Goggins M. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. *Clin Gastroenterol Hepatol* 2013; **11**: 719-730.e5 [PMID: 23200980 DOI: 10.1016/j.cgh.2012.11.016]

37 **Sasaki S**, Yamamoto H, Kaneto H, Ozeki I, Adachi Y, Takagi H, Matsumoto T, Itoh H, Nagakawa T, Miyakawa H, Muraoka S, Fujinaga A, Suga T, Satoh M, Itoh F, Endo T, Imai K. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. *Oncol Rep* 2003; **10**: 21-25 [PMID: 12469138 DOI: 10.3892/or.10.1.21]

38 **Schoedel KE**, Finkelstein SD, Ohori NP. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. *Diagn Cytopathol* 2006; **34**: 605-608 [PMID: 16900481 DOI: 10.1002/dc.20511]

39 **Pea A**, Yu J, Rezaee N, Luchini C, He J, Dal Molin M, Griffin JF, Fedor H, Fesharakizadeh S, Salvia R, Weiss MJ, Bassi C, Cameron JL, Zheng L, Scarpa A, Hruban RH, Lennon AM, Goggins M, Wolfgang CL, Wood LD. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. *Ann Surg* 2017; **266**: 133-141 [PMID: 27433916 DOI: 10.1097/SLA.0000000000001817]

40 **Garcia-Carracedo D**, Chen ZM, Qiu W, Huang AS, Tang SM, Hruban RH, Su GH. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. *Pancreas* 2014; **43**: 245-249 [PMID: 24518503 DOI: 10.1097/MPA.0000000000000034]

41 **Yu J**, Sadakari Y, Shindo K, Suenaga M, Brant A, Almario JAN, Borges M, Barkley T, Fesharakizadeh S, Ford M, Hruban RH, Shin EJ, Lennon AM, Canto MI, Goggins M. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. *Gut* 2017; **66**: 1677-1687 [PMID: 27432539 DOI: 10.1136/gutjnl-2015-311166]

42 **Garcia-Carracedo D**, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. *Clin Cancer Res* 2013; **19**: 6830-6841 [PMID: 24132918 DOI: 10.1158/1078-0432.CCR-13-0624]

43 **Schönleben F**, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, Remotti HE, Su GH. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. *Clin Cancer Res* 2006; **12**: 3851-3855 [PMID: 16778113 DOI: 10.1158/1078-0432.CCR-06-0292]

44 **Singhi AD**, McGrath K, Brand RE, Khalid A, Zeh HJ, Chennat JS, Fasanella KE, Papachristou GI, Slivka A, Bartlett DL, Dasyam AK, Hogg M, Lee KK, Marsh JW, Monaco SE, Ohori NP, Pingpank JF, Tsung A, Zureikat AH, Wald AI, Nikiforova MN. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. *Gut* 2017 [PMID: 28970292 DOI: 10.1136/gutjnl-2016-313586]

45 **Al-Haddad M**, DeWitt J, Sherman S, Schmidt CM, LeBlanc JK, McHenry L, Coté G, El Chafic AH, Luz L, Stuart JS, Johnson CS, Klochan C, Imperiale TF. Performance characteristics of molecular (DNA) analysis for the diagnosis of mucinous pancreatic cysts. *Gastrointest Endosc* 2014; **79**: 79-87 [PMID: 23845445 DOI: 10.1016/j.gie.2013.05.026]

46 **Shen J**, Brugge WR, Dimaio CJ, Pitman MB. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. *Cancer* 2009; **117**: 217-227 [PMID: 19415731 DOI: 10.1002/cncy.20027]

47 **Lennon AM**, Wolfgang C. Cystic neoplasms of the pancreas. *J Gastrointest Surg* 2013; **17**: 645-653 [PMID: 23340991 DOI: 10.1007/s11605-012-2072-6]

48 **Jais B**, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, Bassi C, Manfredi R, Moran R, Lennon AM, Zaheer A, Wolfgang C, Hruban R, Marchegiani G, Fernández Del Castillo C, Brugge W, Ha Y, Kim MH, Oh D, Hirai I, Kimura W, Jang JY, Kim SW, Jung W, Kang H, Song SY, Kang CM, Lee WJ, Crippa S, Falconi M, Gomatos I, Neoptolemos J, Milanetto AC, Sperti C, Ricci C, Casadei R, Bissolati M, Balzano G, Frigerio I, Girelli R, Delhaye M, Bernier B, Wang H, Jang KT, Song DH, Huggett MT, Oppong KW, Pererva L, Kopchak KV, Del Chiaro M, Segersvard R, Lee LS, Conwell D, Osvaldt A, Campos V, Aguero Garcete G, Napoleon B, Matsumoto I, Shinzeki M, Bolado F, Fernandez JM, Keane MG, Pereira SP, Acuna IA, Vaquero EC, Angiolini MR, Zerbi A, Tang J, Leong RW, Faccinetto A, Morana G, Petrone MC, Arcidiacono PG, Moon JH, Choi HJ, Gill RS, Pavey D, Ouaïssi M, Sastre B, Spandre M, De Angelis CG, Rios-Vives MA, Concepcion-Martin M, Ikeura T, Okazaki K, Frulloni L, Messina O, Lévy P. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). *Gut* 2016; **65**: 305-312 [PMID: 26045140 DOI: 10.1136/gutjnl-2015-309638]

49 **Krishna SG**, Brugge WR, Dewitt JM, Kongkam P, Napoleon B, Robles-Medranda C, Tan D, El-Dika S, McCarthy S, Walker J, Dillhoff ME, Manilchuk A, Schmidt C, Swanson B, Shah ZK, Hart PA, Conwell DL. Needle-based confocal laser endomicroscopy for the diagnosis of pancreatic cystic lesions: an international external interobserver and intraobserver study (with videos). *Gastrointest Endosc* 2017; **86**: 644-654.e2 [PMID: 28286093 DOI: 10.1016/j.gie.2017.03.002]

50 **Law JK**, Ahmed A, Singh VK, Akshintala VS, Olson MT, Raman SP, Ali SZ, Fishman EK, Kamel I, Canto MI, Dal Molin M, Moran RA, Khashab MA, Ahuja N, Goggins M, Hruban RH, Wolfgang CL, Lennon AM. A systematic review of solid-pseudopapillary neoplasms: are these rare lesions? *Pancreas* 2014; **43**: 331-337 [PMID: 24622060 DOI: 10.1097/MPA.0000000000000061]

51 **Banks PA**, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013; **62**: 102-111 [PMID: 23100216 DOI: 10.1136/gutjnl-2012-302779]

**P-Reviewer:** Agrawal S, Amornyotin S, Lee CL, Toshniwal JJ **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and Hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): D

Grade E (Poor): 0

**Figure 1 Algorithm for endoscopic ultrasound-guided needle-based confocal laser endomicroscopy imaging biomarker analysis for the evaluation of pancreatic cystic lesions.** nCLE: Needle-based confocal laser endomicroscopy; IPMN: Intraductal papillary mucinous neoplasm;MCN: Mucinous cystic neoplasm;SCA: Serous cystadenoma; PC: Pseudocyst.

**Figure 2 Proposed algorithm for cyst fluid molecular biomarker for the evaluation of pancreatic cystic lesions.** IPMN: Intraductal papillary mucinous neoplasm;MCN: Mucinous cystic neoplasm;SPN: Solid pseudopapillary neoplasm;SCA: Serous cystadenoma.



**Figure 3 Confocal endomicroscopy findings of various types of pancreatic cystic lesions.** A: Papillae of intraductal papillary mucinous neoplasm; B: Epithelial bands of mucinous cystic neoplasm; C: Fern pattern of serous cystadenoma; D: Bright particles against a dark background of pseudocyst; E: Trabecular pattern of neuroendocrine neoplasm.

**Table 1 Summary of major trials investigating role of endoscopic ultrasound guided needle based confocal laser endomicroscopy in the diagnosis of pancreatic cystic lesions**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Study outcome** | **Patients (*n*)** | **Surgery** | **Sensitivity** | **Specificity** | **Accuracy** |
| Inspect[15] | Neoplastic cyst | 66 | 14 (21.2%) | 59 | 100 | 71 |
| Detect[23] | Mucinous cyst | 30 | 2 (6%) | 80 | 100 | 89 |
| Contact-1[19] | SCA | 31 | 7 (22.5%) | 69 | 100 | 87 |
| Contact-2[17] | Mucinous cyst | 33 | 9 (27.3%) | 91 | 95 | 94 |
| Index[24] | Mucinous cyst | 30 | 22 (73.3%) | 88 | 100 | 93 |

SCA: Serous cystadenoma.

**Table 2 Summary of imaging (****endoscopic ultrasound-needle-based confocal laser endomicroscopy) and molecular (cyst-fluid) biomarkers characteristic of different types of pancreatic cystic lesions**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **IPMN** | **MCN** | **SCA** | **SPN** | **PC** | **NEN** |
| Imaging biomarker | | | | | | |
| nCLE patterns | Finger-like Papillae[17,24]  Rope ladder or branched type vascularity[49] | Epithelial bands  (single or multiple)[17]  Rope ladder or branched type vascularity[49] | Fern pattern or superficial vascular network[17,19] | Not well defined | Bright particles against dark background[17] | Trabecular pattern[17] |
| Molecular biomarker | | | | | | |
| Cyst fluid molecular analysis | KRAS, GNAS, RNF43 positive[25,31,34] | KRAS, RNF43 positive, GNAS negative[25,31] | VHL positive[29] | CTNNB1 positive[25] | Negative | Not well characterized |
| Cysts with advanced neoplasia | TP53, SMAD4, PIK3CA, PTEN, CKDN2A positive[35,38,37] | TP53, SMAD4, PIK3CA, PTEN, CKDN2A positive[31] |  |  |  |  |
|  | p16, p53 positive[37] |  |  |  |  |  |

nCLE: Needle-based confocal laser endomicroscopy; IPMN: Intraductal papillary mucinous neoplasm; MCN: Mucinous cystic neoplasm; SCA: Serous cystadenoma; SPN: Solid pseudopapillary neoplasm; PC: Pseudocyst; NEN: Neuroendocrine neoplasm; Advanced neoplasia: Presence of high-grade dysplasia and/or adenocarcinoma.